Related Experiment Videos
Fulminant hepatitis after flutamide treatment
S P Dourakis1, A A Alexopoulou, S J Hadziyannis
1Academic Department of Medicine, Hippokration General Hospital, Athens, Greece.
Journal of Hepatology
|March 1, 1994
Summary
Flutamide, used for prostate cancer, can cause severe acute hepatitis with jaundice and liver failure. This drug-induced liver injury can be fatal, highlighting the need for careful monitoring during treatment.
Area of Science:
- Hepatology
- Oncology
- Clinical Toxicology
Background:
- Flutamide is a nonsteroidal antiandrogen medication commonly prescribed for metastatic prostatic carcinoma.
- Drug-induced liver injury (DILI) is a significant concern in patients undergoing long-term cancer therapy.
Observation:
- Two patients with metastatic prostatic carcinoma developed severe acute hepatitis after 6-8 weeks of flutamide treatment.
- Clinical presentation included jaundice, elevated aminotransferases, hepatic encephalopathy, and prolonged prothrombin time.
Findings:
- Liver histology revealed extensive hepatic necrosis in both cases.
- The findings suggest flutamide can induce acute hepatitis, potentially leading to a fulminant and lethal course.
- Cholestatic side effects are known, but acute hepatitis represents a severe, potentially fatal, adverse event.
Implications:
- Healthcare providers should be vigilant for signs of acute hepatitis in patients treated with flutamide.
- Early detection and discontinuation of flutamide may be crucial to prevent severe liver failure.
- Further research into the mechanisms of flutamide-induced hepatotoxicity is warranted.